Disc Medicine, Inc. Announces Pricing of Upsized Underwritten Offering of Common Stock and Pre-Funded Warrants

Disc Medicine announces $225.5 million upsized stock offering, with proceeds to fund clinical development and commercialization efforts.

Quiver AI Summary

Disc Medicine, Inc. has announced the pricing of its upsized underwritten offering, which includes 3,918,182 shares of common stock priced at $55.00 each, alongside pre-funded warrants for an additional 181,818 shares, priced at $54.9999 each. The total gross proceeds from this offering are expected to be approximately $225.5 million, excluding the exercise of the pre-funded warrants. The company plans to use the proceeds to advance research and clinical development of its product candidates, including aims for commercialization of bitopertin for specific hematologic diseases, along with general corporate purposes. The offering is set to close on January 24, 2025, pending customary closing conditions, with Jefferies, Leerink Partners, Stifel, and Cantor acting as joint book-running managers.

Potential Positives

• The company has successfully upsized its underwritten offering, indicating strong investor interest and confidence in its growth potential.
• Disc Medicine is expected to raise approximately $225.5 million in gross proceeds, which will significantly enhance its financial resources for R&D and commercialization efforts.
• The offering's funds are earmarked for critical developmental activities related to its promising therapeutic candidates, particularly for serious hematologic diseases.
• The 30-day option granted to underwriters could lead to additional capital inflows, further strengthening the company's financial position.

Potential Negatives

• The company is issuing a significant number of new shares, which may dilute existing shareholders' equity and affect the stock price negatively.
• The need for a capital raise through an upsized offering suggests potential financial challenges or instability in funding current operations without external financing.
• The cautionary statement regarding forward-looking statements indicates that the company's future prospects are uncertain, highlighting risks that may deter investors.

FAQ

What is the offering price for Disc Medicine's common stock?

The common stock is being offered at a price of $55.00 per share.

How many shares is Disc Medicine offering in this deal?

Disc Medicine is offering a total of 3,918,182 shares of common stock.

What are pre-funded warrants being sold for?

Pre-funded warrants are being sold at an offering price of $54.9999 each, allowing investors to purchase common stock.

What is the expected gross proceeds from the offering?

The aggregate gross proceeds are expected to be approximately $225.5 million before expenses.

When is the offering expected to close?

The offering is expected to close on January 24, 2025, subject to closing conditions.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$IRON Insider Trading Activity

$IRON insiders have traded $IRON stock on the open market 37 times in the past 6 months. Of those trades, 0 have been purchases and 37 have been sales.

Here’s a breakdown of recent trading of $IRON stock by insiders over the last 6 months:

• JOHN D QUISEL (Chief Executive Officer) has made 0 purchases and 9 sales selling 45,623 shares for an estimated $2,901,728.
• WILLIAM JACOB SAVAGE (Chief Medical Officer) has made 0 purchases and 8 sales selling 26,341 shares for an estimated $1,621,479.
• WILLIAM RICHARD WHITE has made 0 purchases and 17 sales selling 11,653 shares for an estimated $670,217.
• RAHUL KHARA (Chief Legal Officer) has made 0 purchases and 3 sales selling 7,500 shares for an estimated $470,657.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IRON Hedge Fund Activity

We have seen 81 institutional investors add shares of $IRON stock to their portfolio, and 38 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• PARADIGM BIOCAPITAL ADVISORS LP removed 1,206,998 shares (-44.6%) from their portfolio in Q3 2024, for an estimated $59,311,881
• BLACKROCK, INC. added 413,611 shares (+28.8%) to their portfolio in Q3 2024, for an estimated $20,324,844
• JANUS HENDERSON GROUP PLC added 303,954 shares (+68.2%) to their portfolio in Q3 2024, for an estimated $14,936,299
• POLAR CAPITAL HOLDINGS PLC removed 244,928 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $12,035,761
• STATE STREET CORP added 235,115 shares (+39.7%) to their portfolio in Q3 2024, for an estimated $11,553,551
• PERCEPTIVE ADVISORS LLC removed 166,420 shares (-30.1%) from their portfolio in Q3 2024, for an estimated $8,177,878
• ARMISTICE CAPITAL, LLC added 160,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $7,862,400

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

WATERTOWN, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of its upsized underwritten offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. Disc is selling 3,918,182 shares of common stock and pre-funded warrants to purchase 181,818 shares of common stock in the offering. The shares of common stock are being sold at an offering price of $55.00 per share, and the pre-funded warrants are being sold at an offering price of $54.9999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Disc from this offering are expected to be approximately $225.5 million, before deducting underwriting discounts and commissions and other offering expenses, excluding the exercise of any pre-funded warrants. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional $33.825 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities being sold in the offering are being offered by Disc. The offering is expected to close on January 24, 2025, subject to the satisfaction of customary closing conditions.

Disc intends to use the net proceeds from the offering to fund research and clinical development of its current or additional product candidates, to support the potential commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), as well as for working capital and other general corporate purposes.

Jefferies, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the offering. BMO Capital Markets, LifeSci Capital, Wedbush PacGrow and H.C. Wainwright & Co. are acting as co-managers for the offering.

The securities described above are being offered by Disc pursuant to an automatic shelf registration statement on Form S-3 (No. 333-281359) that was previously filed with the Securities and Exchange Commission (SEC) on August 8, 2024. This offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at prospectus_department@jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, (800) 808-7525 ext. 6105 or by email at syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York, 10022, or by email at prospectus@cantor.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Disc Medicine

Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements related to Disc’s expectations regarding the timing and closing of the offering, and the anticipated use of proceeds from the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These risks and uncertainties include fluctuations in Disc’s stock price, changes in market conditions, the satisfaction of customary closing conditions related to the underwritten offering, and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and in the prospectus supplement related to the offering we will file with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Media Contact



Peg Rusconi


Deerfield Group


peg.rusconi@deerfieldgroup.com

Investor Relations Contact



Christina Tartaglia


Precision AQ


christina.tartaglia@precisionaq.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.